{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T12:40:23Z","timestamp":1787488823875,"version":"build-2736575974"},"reference-count":49,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,11,28]]},"DOI":"10.1536\/ihj.20-346","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T22:07:15Z","timestamp":1605218835000},"page":"1174-1182","source":"Crossref","is-referenced-by-count":11,"title":["The Effect of Renin-Angiotensin System Inhibitors on the Recurrence of Atrial Fibrillation After Catheter Ablation"],"prefix":"10.1536","volume":"61","author":[{"given":"Jianqiang","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengui","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangrong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Atrial fibrillation Center, The First Affiliated Hospital of Zhejiang University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zielonka A, Tkaczyszyn M, Mende M, <i>et al<\/i>. Atrial fibrillation in outpatients with stable coronary artery disease: results from the multicenter RECENT study. Pol Arch Med Wewn 2015; 125: 162-71.","DOI":"10.20452\/pamw.2709"},{"key":"2","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.hrthm.2007.04.005","volume":"4","year":"2007","unstructured":"2. Calkins H, Brugada J, Packer DL, <i>et al<\/i>. HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-Up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816-61.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"3","unstructured":"3. Weerasooriya R, Khairy P, Litalien J, <i>et al<\/i>. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 2011; 57: 160-6."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Arai M, Okumura Y, Nagashima K, <i>et al<\/i>. Adverse clinical events during long-term follow-up after catheter ablation of atrial fibrillation. Int Heart J 2019; 60: 812-21.","DOI":"10.1536\/ihj.18-517"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Xu Y, Sharma D, Li G, Liu Y. Atrial remodeling: new pathophysiological mechanism of atrial fibrillation. Med Hypotheses 2013; 80: 53-6.","DOI":"10.1016\/j.mehy.2012.10.009"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-9.","DOI":"10.1016\/j.jacc.2007.09.064"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Greiser M, Schotten U. Dynamic remodeling of intracellular Ca (2+) signaling during atrial fibrillation. J Mol Cell Cardiol 2013; 58: 134-42.","DOI":"10.1016\/j.yjmcc.2012.12.020"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. January CT, Wann LS, Alpert JS, <i>et al<\/i>. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the heart Rhythm Society. Circulation 2014; 130: e199-267.","DOI":"10.1161\/CIR.0000000000000041"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.","DOI":"10.1016\/S0735-1097(03)00464-9"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Vermes E, Tardif JC, Bourassa MG, <i>et al<\/i>. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.","DOI":"10.1161\/01.CIR.0000072793.81076.D4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Maggioni AP, Latini R, Carson PE, <i>et al<\/i>. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-57.","DOI":"10.1016\/j.ahj.2004.09.033"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yin Y, Dalal D, Liu Z, <i>et al<\/i>. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27: 1841-6.","DOI":"10.1093\/eurheartj\/ehl135"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Healey JS, Baranchuk A, Crystal E, <i>et al<\/i>. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.","DOI":"10.1016\/j.jacc.2004.11.070"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Schneider MP, Hua TA, B\u00f6hm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-307.","DOI":"10.1016\/j.jacc.2010.01.043"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Li TJ, Zang WD, Chen YL, Geng N, Ma SM, Li XD. Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis. Int J Clin Pract 2013; 67: 536-43.","DOI":"10.1111\/ijcp.12063"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhang Y, Ma L. Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery. Eur J Cardio Thorac Surg 2015; 47: 788-95.","DOI":"10.1093\/ejcts\/ezu298"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Wang Q, Shang Y, Wang Z, <i>et al<\/i>. Perindopril for the prevention of atrial fibrillation recurrence after radiofrequency catheter ablation: one-year experience. Heart Rhythm 2016; 13: 2040-7.","DOI":"10.1016\/j.hrthm.2016.06.039"},{"key":"18","unstructured":"18. Wu J, Luo C, Ou YZ. Amiodarone and losartan on recurrence and atrial structure for chronic atrial fibrillation after RFCA. Chin J Clin Pharmacol Ther 2015; 20: 318-22."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cui Y, Ma C, Long D, Wang L, Cao X, Zhang G. Effect of valsartan on atrial fibrillation recurrence following pulmonary vein isolation in patients. Exp Ther Med 2015; 9: 631-5.","DOI":"10.3892\/etm.2014.2143"},{"key":"20","unstructured":"20. Tian F, Sun P, Zhang Y. Effects of candesartan on relapse of atrial fibrillation after radio-frequency ablation and duration of atrial fibrillation attack. Int J Clin Exp Med 2019; 12: 1011-7."},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Tayebjee MH, Creta A, Moder S, <i>et al<\/i>. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation. Europace 2010; 12: 1537-42.","DOI":"10.1093\/europace\/euq284"},{"key":"22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/europace\/eup387","volume":"12","year":"2010","unstructured":"22. Patel D, Mohanty P, Di Biase L, <i>et al<\/i>. The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. Europace 2010; 12: 322-30.","journal-title":"Europace","ISSN":"https:\/\/id.crossref.org\/issn\/1099-5129","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-12.","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"24","unstructured":"24. Higgins JPT, Green S, eds. <i>Cochrane Handbook for Systematic Reviews of Interventions<\/i> Version 5.1.0; updated March 2011 The Cochrane Collaboration: 2011. Available at: http:\/\/handbook.cochrane.org"},{"key":"25","unstructured":"25. Wells G, Shea B, O&apos;Connell D, <i>et al<\/i>. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2013. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed June 30, 2017."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Al Chekakie MO, Akar JG, Wang F, <i>et al<\/i>. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18: 942-6.","DOI":"10.1111\/j.1540-8167.2007.00887.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Park JH, Oh YS, Kim JH, <i>et al<\/i>. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on patients following ablation of atrial fibrillation. Korean Circ J 2009; 39: 185-9.","DOI":"10.4070\/kcj.2009.39.5.185"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zheng B, Kang J, Tian Y, <i>et al<\/i>. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers have no beneficial effect on ablation outcome in chronic persistent atrial fibrillation. Acta Cardiol 2009; 64: 335-40.","DOI":"10.2143\/AC.64.3.2038018"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Klemm HU, Heitzer T, Ruprecht U, Meinertz T, Ventura R. Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation. Cardiology 2010; 117: 14-20.","DOI":"10.1159\/000318016"},{"key":"31","unstructured":"31. Berkowitsch A, Neumann T, Kuniss M, <i>et al<\/i>. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder? Pacing Clin Electrophysiol 2010; 33: 1101-11."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Ishikawa K, Yamada T, Yoshida Y, <i>et al<\/i>. Renin-angiotensin system blocker use may be associated with suppression of atrial fibrillation recurrence after pulmonary vein isolation. Pacing Clin Electrophysiol 2011; 34: 296-303.","DOI":"10.1111\/j.1540-8159.2010.02949.x"},{"key":"33","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.hrthm.2015.06.007","volume":"12","year":"2015","unstructured":"33. Mohanty S, Mohanty P, Trivedi C, <i>et al<\/i>. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction. Heart Rhythm 2015; 12: 1963-71.","journal-title":"Heart Rhythm","ISSN":"https:\/\/id.crossref.org\/issn\/1547-5271","issn-type":"print"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Wyler von Ballmoos MC, Ware JH, Haring B. Clinical research quo vadis? Trends in reporting of clinical trials and observational study designs over two decades. J Clin Med Res 2015; 7: 428-34.","DOI":"10.14740\/jocmr2115w"},{"key":"35","unstructured":"35. Whelton PK, Carey RM, Aronow WS, <i>et al<\/i>. ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines. J Am Coll Cardiol 2017; 71: e127-248[published correction appears in J Am Coll Cardiol 2018 May 15; 71: 2275-9]."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. GISSI-AF Investigators, Disertori M, Latini R, <i>et al<\/i>. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-17.","DOI":"10.1056\/NEJMoa0805710"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. K\u00fchlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR\/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000; 36: 139-46.","DOI":"10.1016\/S0735-1097(00)00693-8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Kirchhof P, Fabritz L. Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension. Eur Heart J 2014; 35: 1169-71.","DOI":"10.1093\/eurheartj\/ehu068"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Hamdani N, Paulus WJ. Treatment of heart failure with normal ejection fraction. Curr Treat Options Cardiovasc Med 2011; 13: 26-34.","DOI":"10.1007\/s11936-010-0103-8"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Makkar KM, Sanoski CA, Spinler SA. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 2009; 29: 31-48.","DOI":"10.1592\/phco.29.1.31"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27: 512-8.","DOI":"10.1093\/eurheartj\/ehi668"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Tu DN, Liao YH, Zou AR, <i>et al<\/i>. Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes. Acta Pharmacol Sin 2008; 29: 913-22.","DOI":"10.1111\/j.1745-7254.2008.00839.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Boldt A, Scholl A, Garbade J, <i>et al<\/i>. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 2006; 101: 261-7.","DOI":"10.1007\/s00395-005-0571-2"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-61.","DOI":"10.1016\/S0008-6363(02)00243-2"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Chung MK, Martin DO, Sprecher D, <i>et al<\/i>. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-91.","DOI":"10.1161\/hc4901.101760"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Stanciu AE, Vatasescu RG, Stanciu MM, Serdarevic N, Dorobantu M. The role of pro-fibrotic biomarkers in paroxysmal and persistent atrial fibrillation. Cytokine 2018; 103: 63-8.","DOI":"10.1016\/j.cyto.2017.12.026"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47. Suzuki T, Yamazaki T, Ogawa S, Nagai R, Yamashita T, J-RHYTHM II Investigators. Echocardiographic predictors of frequency of paroxysmal atrial fibrillation (AF) and its progression to persistent AF in hypertensive patients with paroxysmal AF: results from the Japanese Rhythm Management Trial II for atrial fibrillation (J-RHYTHM II Study). Heart Rhythm 2011; 8: 1831-6.","DOI":"10.1016\/j.hrthm.2011.07.035"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Nademanee K, McKenzie J, Kosar E, <i>et al<\/i>. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol 2004; 43: 2044-53.","DOI":"10.1016\/j.jacc.2003.12.054"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Stroup DF, Berlin JA, Morton SC, <i>et al<\/i>. Meta-analysis of observational studies in epidemiology. A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-12.","DOI":"10.1001\/jama.283.15.2008"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-346\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T03:46:33Z","timestamp":1606535193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/6\/61_20-346\/_article"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2020,11,28]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-346","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,28]]}}}